CAMP4 THERAPEUTICS RECEIVES CLINICAL TRIAL APPLICATION APPROVAL FOR PHASE 1/2 CLINICAL TRIAL OF CMP-002 IN PATIENTS WITH SYNGAP1-RELATED DISORDER IN THE EUROPEAN UNION

Reuters · 4d ago

Please log in to view news